Total
0
Shares
Acrux (ASX:ACR) - Managing Director & CEO, Michael Kotsanis - The Market Herald
Managing Director & CEO, Michael Kotsanis
Source: Acrux
  • Acrux (ACR) has announced its subsidiary, Acrux DDS, has entered an exclusive sales, marketing and distribution agreement with TruPharma
  • Subject to FDA approval, TruPharma will commercialise six unnamed products from Acrux's portfolio
  • It will also management and sponsor each FDA application as well as the commercial manufacturing and distribution of each product
  • The 10-year agreement will see Acrux and TruPharma share the gross profits generated from product sales
  • Company shares have gone up a healthy 29.6 per cent and are trading for 17.5 cents each

Acrux (ACR) has announced its subsidiary, Acrux DDS, has entered a 10-year exclusive sales, marketing and distribution agreement with TruPharma in the U.S.

Essentially, TruPharma distributes high-quality prescription pharmaceutical products to the U.S. market. It partners with reliable developers and manufactures to bring niche and limited supply products to its customers.

Subject to approval by the U.S. Food and Drug Administration (FDA), TruPharma will be responsible for commercialising six of Acrux's existing products. It will also be responsible for the sponsorship and management of each FDA application, management of commercial manufacturing, marketing and the distribution of each product.

"We are excited to enter into this agreement with TruPharma and we look forward to developing a long-lasting relationship between the two companies," Acrux CEO and Managing Director Michael Kotsanis said.

These selected products are at various stages of development and have not been lodged with the FDA.

Acrux will continue to conduct the development, scientific and bio-equivalence activities to develop its generic products and seek FDA approval.

The company develops a range of topical products and has an expanding pipeline of products under development.

However, generic product development is usually less time-consuming, costly and complex than the new chemical entity development process. It generally doesn't require new preclinical and clinical studies.

Acrux has a portfolio pipeline of 14 products, two of which have received FDA approval. Out of the 14 products, 11 have not yet been disclosed and are still in the formulation and process development phases.

Acrux and TruPharma will share the gross profits generated from the product sales.

Company shares have gone up a healthy 29.6 per cent and are trading for 17.5 cents each at 11:33 am AEST.


Subscribe


ACR by the numbers
More From The Market Herald
OBJ (ASX:OBJ) - CEO, Paul Peros - The Market Herald

" OBJ (ASX:OBJ) to raise $4.5M for product development and licencing

Innovative wellness company OBJ (OBJ) is aiming to raise $4.5 million through an entitlement offer and placement for licencing, development and general workin…
Creso Pharma (ASX:CPH) - CEO & Co Founder, Dr Miri Halperin Wernli (left) and Chairman, Boaz Wachtel (right) - The Market Herald

" Creso Pharma (ASX:CPH) subsidiary receives follow-up order from Univo Pharmaceuticals

Creso Pharma’s (CPH) subsidiary, Mernova Medicinal, has received a US$625,690 (roughly A$901,830) purchase order from Univo Pharmaceuticals.
Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka - The Market Herald

" Holista CollTech (ASX:HCT) misses the mark for hand sanitiser product

Holista CollTech (HCT) has downgraded its $3.8 million in expected sales from its hand sanitiser product, Natshield, due to COVID-19 and race riots.
Cellmid (ASX:CDY) - CEO, Maria Halasz (right) - The Market Herald

" Cellmid (ASX:CDY) signs distribution agreement for SARS-CoV-2 and ELISA’s

Cellmid (CDY) has signed a distribution agreement with Immunodiagnostics (IMD) for Enzyme Linked Immunosorbent Assays (ELISA’s) and SARS-CoV-2 tests in Australia and New